Fundraising FoxTMC Venture Fund — 2024 Investments
2 investments dated 2024 · listed companies and verified rows first · show all
CrossBridge Bio, launched in 2023, develops next-generation antibody-drug conjugates (ADCs) to address a range of cancer indications.
BiotechHealthtechHouston, US
Kyoji Tsuchikama(Executive Officer, Director, Promoter)Michael Torres(Executive Officer, Director, Promoter)
BoardWilliam F. McKeon(Director)Damir Illich(Director)Patrick James Crutcher(Director)
Co-investorsPortal InnovationsPortal
Motif Neurotech develops a therapeutic brain-computer interface using minimally invasive neuromodulation to treat difficult-to-treat mental health conditions such as depression.
BiotechDeep TechDigital HealthHealthtechMedical DevicesHouston, US
Sameer Sheth(Founder)inSunil Sheth(Founder)Nick Halper(Chief Operating Officer)inSteve Goetz(Chief Technology Officer)inAnthony Arnold(Director)inKaiyuan Yang(Founder)
Co-investorsArboretum VenturesDivergent CapitalDolby Family VenturesFeatures Capital HoldingsPsyMed VenturesXEIA Venture Partners+6 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.